21 – 30 of 31
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients
(
- Contribution to journal › Article
- 2012
-
Mark
IGHV3-21 Gene Frequency in a Swedish Cohort of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
(
- Contribution to journal › Article
-
Mark
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur
(
- Contribution to journal › Article
-
Mark
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies
(
- Contribution to journal › Article
- 2011
-
Mark
Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia
(
- Contribution to journal › Article
-
Mark
T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
(
- Contribution to journal › Article
- 2010
-
Mark
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
(
- Contribution to journal › Article
- 2009
-
Mark
Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma.
(
- Contribution to journal › Article
-
Mark
(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
(
- Contribution to journal › Article